Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05515159
Other study ID # 51089
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date October 1, 2019
Est. completion date October 1, 2029

Study information

Verified date September 2023
Source Haukeland University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The present multi-disciplinary study will assess blood biomarkers to investigate putative mechanisms of action of ECT. Laboratory findings will be correlated to clinical parameters, cognitive measures and psychometric outcome measures. The aim is to elucidate the underlying mechanisms for both treatment effects and cognitive side effects of ECT.


Description:

Study hypothesis That a combined dataset of biomarker and clinical/ demographic data can be used to identify possible mechanisms of action for ECT or pathophysiological mechanisms underlying major depression. The study is based on already (prospectively, observational) collected data and biological material: - in the Regional ECT Register (Regionalt medisinsk kvalitetsregister for nevrostimulerende behandling i Helse Vest, Datatilsynets konsesjon 2012/5490), - the ECT-MRI study approved by REK sørøst "2013/1032 ECT and neuroradiology" with its study specific biobank (Imdep) - and the ECT biobank, (Forskningsbiobanken for nevrostimulerende behandling i Helse Vest (REK Vest 2017/925). Biological samples and demographic/clinical data from those sources will be analyzed together. All patients received the standard ECT treatment, as it is provided at the ECT-department at the Haukeland University Hospital. Inclusion criteria: Patients (age > 18) referred to the ECT-unit and accepted for treatment. Exclusion criteria: Patients unable to give informed consent Data from the current study will be compared to data from the control groups in the ECT-MRI study: 1. a group of patients undergoing ECV for AF (controls 1) and 2. healthy controls undergoing the same investigations as the ECT patient group, but not receiving ECT or anesthesia (controls 2). Clinical assessments Clinical assessments and monitoring was performed in accordance with the routine assessments at the section for ECT , Haukeland US and described in the Regional Register for ECT (Regionalt medisinsk kvalitetsregister for nevrostimulerende behandling i Helse Vest, Datatilsynets konsesjon 2012/5490). Blood and saliva biomarkers We will analyze DNA, RNA and blood biomarkers that may be relevant for several hypotheses related to possible pathophysiological mechanisms of major depression, possible mechanisms of action of ECT and changes in biomarkers during depression treatment. Due to the constant progress in the field, the decision on which markers to analyze and how to perform the analyses should not be taken too early. However, candidate markers include neurotrophic factors (e.g. BDNF, CREB), neurotransmitters (e.g. GABA/Glutamate and relevant genetic markers), inflammation factors and markers of damage to the blood-brain barrier. Further, we will assess metabolomic changes from pre to post-treatment and other relevant blood biomarkers. Genetic analysis (DNA, RNA), such as changes in RNA and DNA methylation from pre to posttreatment, might identify putative areas that are important for the biological mechanisms underlying ECT response and associated with depression /disease development. Further analyses might include Genome-wide association analyses of severe/ treatment resistant depression (GWAS) (patients vs healthy controls), Genome-wide association analyses of ECT response (responders vs nonresponders) and Epigenome-wide association (EWA) analyses of ECT response. Studies so far suggest that effects of therapy of psychiatric disorders may be detected in peripheral blood. The information on methylation will be collected from both blood and saliva, and EWA analyses will also be performed on both. We will utilize longitudinal data to examine changes in methylation of ECT responders, non-responders and controls to establish possibly long-term and short-term epigenetic changes associated with ECT. Metabolic and Proteomic analyses of ECT response In ongoing studies, we recently observed significant effects of ECT on serum tryptophan metabolites, including neuroprotective kynurenines. In this study, we will continue our analyses by increasing the sample size and expanding the number of metabolites and proteins that we will examine in relation to ECT response.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 100
Est. completion date October 1, 2029
Est. primary completion date October 1, 2029
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients (age > 18) referred to the ECT-unit and accepted for treatment. Exclusion Criteria: Patients unable to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
electroconvulsive therapy
electrical stimulation of the brain while the patient is under anesthesia.

Locations

Country Name City State
Norway Haukeland University Hospital Bergen

Sponsors (1)

Lead Sponsor Collaborator
Haukeland University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in levels of blood biomarkers 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A